Anil Chhabra, MD
Cardiovascular Disease · Shreveport, LANPI 1225002918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Novartis at 25.2% of the total. Reporting peaked in 2019 at $1,325 and has fallen 56.8% since, to $573 in 2025.
Across 209 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Medtronic$773
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$372
- Pfizer$338
- Boston Scientific$246
- Sanofi-aventis U.S. LLC$172
- plus $1K from 26 others
Across 844 payments — averaging $2324.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$452K
- Amgen$367K
- Novartis$323K
- Eli Lilly$240K
- AstraZeneca$137K
- Janssen Research & Development, LLC$137K
- plus $306K from 7 others
What the payments were for
- Food & beverage$3,97198%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 70 | $1,022 |
| Medtronic(2 entities) | 15 | $773 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $372 |
| Pfizer | 22 | $338 |
| Boston Scientific | 6 | $246 |
| Sanofi-aventis U.S. LLC | 12 | $172 |
| E.r. Squibb & Sons, L.L.C. | 11 | $160 |
| Cvrx, Inc. | 4 | $123 |
| Abiomed | 3 | $76 |
| Silk Road Medical, Inc. | 1 | $72 |
| GSK | 5 | $72 |
| Idorsia Pharmaceuticals US Inc | 1 | $60 |
| Merck | 4 | $59 |
| Itamar Medical Inc | 2 | $59 |
| Novo Nordisk | 3 | $49 |
| Abbott | 2 | $47 |
| Philips North America LLC | 3 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $42 |
| Astellas Pharma US Inc | 3 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $33 |
| Lundbeck LLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $21 |
| Preventice Services, LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Akcea Therapeutics, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 2 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,059 in reported general payments places this provider in the 55th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 408 | $363,665 |
| EntrestoSacubitril/Valsartan | 177 | $158,225 |
| JardianceEmpagliflozin | 128 | $107,593 |
| XareltoRivaroxaban | 112 | $96,465 |
| MultaqDronedarone Hcl | 63 | $62,050 |
| Repatha SureclickEvolocumab | 50 | $50,339 |
| Rosuvastatin Calcium | 701 | $9,969 |
| Ezetimibe | 459 | $8,842 |
| Metoprolol Succinate | 562 | $7,587 |
| Propafenone Hcl | 81 | $5,657 |
| NexletolBempedoic Acid | 13 | $5,029 |
| Prasugrel Hcl | 48 | $3,167 |
| Atorvastatin Calcium | 317 | $2,914 |
| Diltiazem 12hr ErDiltiazem Hcl | 14 | $2,847 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 253 | $2,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $338 | $363,665408 claims |
| NovartisEntresto | $1,022 | $158,225177 claims |
| Boehringer IngelheimJardiance | $16 | $107,593128 claims |
| Johnson & JohnsonXarelto | $13 | $96,465112 claims |
| Sanofi-aventis U.S. LLCMultaq | $172 | $62,05063 claims |
| Esperion Therapeutics, Inc.Nexletol | $13 | $5,02913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Shreveport
- Basel KasabaliShreveport$30K
- Tina FirouzbakhtShreveport$28K
- Wenwu ZhangShreveport$21K
- William EavesShreveport$15K
- Jagan BeedupalliShreveport$13K
- Mahin KhanShreveport$10K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.